Clinical trials: Vector Borne Diseases
Malaria, Respiratory Infections
A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children
The primary objective of this study is to determine whether addition of azithromycin (AZ) to Seasonal Malaria Chemoprevention (SMC) using sulphadoxine/pyrimethamine (SP) +amodiaquine (AQ) will provide an additional reduction in…
- Trial name
- SMCAZ (NCT02211729)
- Testing
- Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 22,090 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Crimean Congo Hemorrhagic Fever
Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever
This First-in-human dose-escalation vaccine phase I study aims to evaluate safety and reactogenicity of the investigational vaccine N-pVAX1, against Crimean Congo Hemorrhagic Fever, delivered by in vivo EP given as three im doses…
- Trial name
- CCHF-NP-1 (NCT06684431)
- Testing
- N-pVAX1
- Where
- Sweden
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Chikungunya
Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
Chikungunya vaccine is an inactivated virus vaccine. There will be three study arms and subjects will be vaccinated in a dose escalation manner.In each arm, vaccine will be administered on Day 1, Day 29, and Day 57.
- Trial name
- NCT04603131
- Testing
- Inactivated Chikungunya virus vaccine 20 mcg, Inactivated Chikungunya virus vaccine 30 mcg, Inactivated Chikungunya virus vaccine 10 mcg
- Where
- 4 sites in India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Dengue
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
- Trial name
- NCT01702272
- Testing
- Procleix Dengue Virus Assay
- Where
- United States
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Falciparum Malaria
Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine (80%) and more recently an increasing degree of resistance to sulfadoxine-pyrimethamine monotherapy (12%).
- Trial name
- ASPF (NCT01115439)
- Testing
- artesunate plus sulfadoxine-pyrimethamine (AS+SP)
- Where
- 4 sites in Afghanistan
- Volunteers
- 100 people
- Sponsor
- University of Oxford
Falciparum Malaria
Study to Investigate the Induction of an Protective Immune Response to Malaria
The objective of the study is to induce a protective immune response against malaria in healthy human volunteers. The different parts of the immune response will then be studied.
- Trial name
- NCT00442377
- Testing
- exposure to malaria sporozoites
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Treatment of Acute Zika Virus Infection
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans
Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector that transmits Dengue virus, Aedes aegypti.
- Trial name
- NCT03443830
- Testing
- Tyzivumab
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tychan Pte Ltd.
Pneumonia, Bacterial, Viral Infection
Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia
Clinical pneumonia is a leading cause of pediatric hospitalization. The etiology is generally bacterial or viral. Prompt and optimal treatment of pneumonia is critical to reduce mortality.
- Conditions
- Pneumonia, Bacterial, Viral Infection, Clinical Pneumonia, Plasmodium Falciparum Malaria
- Trial name
- NCT03996967
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 837 people
- Sponsor
- Boston University
Malaria
Innovation Platform
In this study, a prospective evaluation of novel malaria diagnostic tools under development will be performed in malaria-endemic countries to assess their clinical performance for detection of malaria at point-of-care (POC).
- Trial name
- NCT04558528
- Testing
- Novel in vitro diagnostics and medical applications
- Where
- 2 sites in Indonesia, Rwanda
- Volunteers
- 640 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Malaria, Malaria Vivax
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria
The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P.
- Conditions
- Malaria, Malaria Vivax, Radical Cure
- Trial name
- SJ733-2002 (NCT07430592)
- Testing
- CQ/TQ, SJ733 (3-day)/TQ, SJ733 (2-day ) /TQ
- Where
- Peru
- Volunteers
- 104 people
- Sponsor
- R. Kiplin Guy
Malaria
IPTi in Mozambican Infants for Malaria Prevention
To evaluate if intermittent preventive treatment in infants (IPTi) consisting of SP [Fansidar] given through the EPI scheme alongside routine immunisations at 3, 4 and 9 months of age reduces de incidence of clinical malaria up…
- Trial name
- NCT00209794
- Testing
- Sulfadoxine-Pyrimethamine (Fansidar)
- Where
- Mozambique
- Volunteers
- 1,498 people
- Sponsor
- Hospital Clinic of Barcelona
Healthy Volunteers
Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
This study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common.
- Trial name
- NCT06408857
- Testing
- MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV
- Where
- 2 sites in Uganda
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Dengue
Study of Dengue in Patients With Autoimmune Diseases During the Epidemics of 2020 and 2021 in Reunion Island
It is not known whether there is a different clinical profile of dengue in patients with immune system dysfunction. Preliminary data and previous literature suggest that autoimmune diseases, and in particular their treatment, may…
- Trial name
- MAIDEN (NCT05852977)
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Malaria, HIV Infections
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
This study is an open-label, single site, randomized controlled trial comparing protease inhibitor (PI)-based antiretroviral therapy (ART) to non-PI based ART for HIV-infected pregnant and breastfeeding women of all CD4 cell…
- Trial name
- PROMOTE-PIs (NCT00993031)
- Testing
- Lopinavir/ritonavir, Efavirenz, Zidovudine
- Where
- Uganda
- Volunteers
- 389 people
- Sponsor
- University of California, San Francisco
Skin Diseases, Parasitic
Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia
The purpose of the study is to evaluate the sensitivity and specificity of CL Detect, in subjects with suspected CL in Tunisia.
- Trial name
- CL Detect™ (NCT01769612)
- Testing
- No Intervention
- Where
- 2 sites in Tunisia
- Volunteers
- 168 people
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria,Falciparum, Malaria
Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities
This community-based cluster randomized controlled trial aims to evaluate the effectiveness of time-limited, community-wide mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHA-PPQ) and single low-dose…
- Trial name
- NCT04864444
- Testing
- Dihydroartemisinin-piperaquine, Primaquine
- Where
- Senegal
- Volunteers
- 10,715 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria
A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S
The purpose of this study is to assess two types of new malaria vaccines in different combinations. The study will enable us to assess: 1. The ability of the vaccines to prevent malaria infection. 2.
- Trial name
- NCT02252640
- Testing
- RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01), ChAd63 ME-TRAP (5 x 10^10 vp)
- Where
- 4 sites in United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali
The purpose of this study is to compare the gametocytocidal and transmission reducing activity of artemether-lumefantrine (AL) with and without a single dose of 0.25mg/kg primaquine (PQ) and sulfadoxine-pyrimethamine with…
- Trial name
- NECTAR3 (NCT05081089)
- Testing
- Artemether-lumefantrine, Primaquine Phosphate, Sulphadoxine-pyrimethamine with amodiaquine
- Where
- Mali
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Scrub Typhus
Scrub Typhus Antibiotic Resistance Trial
Study type: Randomized Control Treatment Trial Study population: Male and female patients with ≥15 years of age and acute scrub typhus Duration: 2 years Study Design: Prospective, open-label, randomized-controlled treatment trial…
- Trial name
- START (NCT03083197)
- Testing
- Doxycycline 7 days, Doxycycline 3 days, Azithromycin 3 days
- Where
- 5 sites in Thailand
- Volunteers
- 177 people
- Sponsor
- University of Oxford
Anaemia, Malaria
Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment
Malaria is one of the major causes of illness and mortality in Sub-Saharan Africa. In Ghana, malaria is the most important cause of morbidity and accounts for about 40% of outpatient contacts.
- Trial name
- NCT00258024
- Testing
- IPT-sulphadoxinepyrimethamine
- Where
- Ghana
- Volunteers
- 420 people
- Sponsor
- DBL -Institute for Health Research and Development